NCT06675565

A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ALN-AGT01 RVR in Adult Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (actual)
• Sponsor: Alnylam Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and PK of single ascending doses of ALN-AGT01 RVR.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	ALN-AGT01 RVR	ALN-AGT01 RVR will be administered subcutaneously (SC)
DRUG	Placebo	Placebo will be administered SC

Timeline

• Start date: 2024-11-05
• Primary completion: 2025-09-08
• Completion: 2025-09-08
• First posted: 2024-11-05
• Last updated: 2025-09-19

Locations

1 site across 1 country: Canada